Skip to content

News · Science & Innovation

Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

Source: ScienceDaily

A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.

This is a short summary of a report by a third-party publisher. Newsline Press did not produce the original reporting.

Read the full story at ScienceDaily

Original publisher: ScienceDaily

Spotted an error? Request a correction · Corrections Policy

Related stories